Form 4: Ionis Pharmaceuticals EVP Eric Swayze Reports Stock Purchase and Sale

Eric Swayze, EVP of Research at Ionis Pharmaceuticals, reports the purchase of common stock and the disposal of common stock held indirectly.

Summary

• On August 30, 2024, Eric Swayze, EVP of Research at Ionis Pharmaceuticals, reported a transaction involving the company's common stock.
• Swayze acquired 11 shares of common stock at a price of $38.641 per share through the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan.
• Swayze also disposed of 34,907 shares of common stock held indirectly by his son.
• Following the reported transactions, Swayze directly owns 85 shares of Ionis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without providing explicit positive or negative commentary. The purchase is mildly positive, while the sale is mildly negative, balancing each other out.

Positives

• The purchase of shares by an executive could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 34,907 shares held indirectly by Swayze's son could be interpreted negatively, although the reason for the disposal is not specified.

Risks

• The inability to sell the purchased shares until February 28, 2025, introduces a risk if the stock price declines before that date.

Industry Context

Executive stock transactions are common and are closely watched by investors for signals about a company's prospects. Purchases can indicate confidence, while sales can raise concerns, although they can also be due to personal financial planning.

Stakeholder Impact

• The stock transactions may influence investor sentiment and potentially affect the stock price.

Key Dates